Autosomal Dominant Polycystic Kidney Disease (ADPKD)OVERTURENCT01430494
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
An observational study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 266 sites in 20 countries.
Trial summary
To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes). Association with total kidney volume changes and other measures of disease progression will be determined in order to identify a population at increased risk… Read more about this study
- Who is it for?
- Ages 12 to 70 years
- Conditions the study is for
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- How many people
- 3,409 participants
- Where
- 266 sitesin 20 countries
- Study dates
- 1 Jun 2011to 1 Oct 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 70 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Subjects will be identified by participating clinics (primarily nephrology clinics) treating patients with ADPKD.
Who may be able to join
- existing diagnosis of ADPKD by modified-Ravine criteria
- Total kidney volume >= 300 cc/m height by ultrasound or >= 250 cc/m height by MRI
Who cannot join
- Current or expected (within the next six months) interventions for the treatment of ADPKD affecting kidney volume
Trial locations and contacts
266 sites in 20 countries.
266 sites in 20 countries
United States102 sites
Otsuka Investigational Site
Aiken, South Carolina, 29801
Otsuka Investigational Site
Albany, New York, 12208
Otsuka Investigational Site
Albuquerque, New Mexico, 87109
Otsuka Investigational Site
Altoona, Pennsylvania, 16601
Otsuka Investigational Site
Anderson, South Carolina, 29621
Otsuka Investigational Site
Arlington, Texas, 76015
Otsuka Investigational Site
Arvada, Colorado, 80002
Otsuka Investigational Site
Atlanta, Georgia, 30322
Otsuka Investigational Site
Augusta, Georgia, 30901
Otsuka Investigational Site
Aurora, Colorado, 80045
Otsuka Investigational Site
Azusa, California, 91702
Otsuka Investigational Site
Bakersfield, California, 93308
Otsuka Investigational Site
Baltimore, Maryland, 21201
Otsuka Investigational Site
Baltimore, Maryland, 21224
Otsuka Investigational Site
Bethesda, Maryland, 20814
Otsuka Investigational Site
Bethlehem, Pennsylvania, 18017
Otsuka Investigational Site
Bluefield, West Virginia, 24701
Otsuka Investigational Site
Boston, Massachusetts, 02111
Otsuka Investigational Site
Boston, Massachusetts, 02215
Otsuka Investigational Site
Brooklyn, New York, 11215
Otsuka Investigational Site
Brooklyn Center, Minnesota, 55430
Otsuka Investigational Site
Buffalo, New York, 14215
Otsuka Investigational Site
Burlington, Vermont, 05401
Otsuka Investigational Site
Chapel Hill, North Carolina, 27599
Otsuka Investigational Site
Chicago, Illinois, 60637
Otsuka Investigational Site
Cincinnati, Ohio, 45267
Otsuka Investigational Site
Cleveland, Ohio, 44106
Otsuka Investigational Site
Columbia, South Carolina, 29203
Otsuka Investigational Site
Columbia, South Carolina, 29209
Otsuka Investigational Site
Columbus, Ohio, 43210
Otsuka Investigational Site
Coral Gables, Florida, 33146
Otsuka Investigational Site
Denver, Colorado, 80210
Otsuka Investigational Site
Detroit, Michigan, 48236
Otsuka Investigational Site
Devils Lake, North Dakota, 58301
Otsuka Investigational Site
Doylestown, Pennsylvania, 18901
Otsuka Investigational Site
Durham, North Carolina, 27705
Otsuka Investigational Site
Fairfax, Virginia, 22030
Otsuka Investigational Site
Fargo, North Dakota, 58122
Otsuka Investigational Site
Flushing, New York, 11355
Otsuka Investigational Site
Forest Hills, New York, 11375
Otsuka Investigational Site
Fort Worth, Texas, 76104
Otsuka Investigational Site
Great Neck, New York, 11021
Otuska Investigational Site
Holyoke, Massachusetts, 01040
Otsuka Investigational Site
Houston, Texas, 77004
Otsuka Investigational Site
Houston, Texas, 77030
Otsuka Investigational Site
Hudson, Florida, 34667
Otsuka Investigational Site
Jacksonville, Florida, 32216
Otsuka Investigational Site
Kalamazoo, Michigan, 49007
Otsuka Investigational Site
Kansas City, Kansas, 66106
Otsuka Investigational Site
Knoxville, Tennessee, 37923
Otsuka Investigational Site
Lancaster, Pennsylvania, 17604
Otsuka Investigational Site
Las Vegas, Nevada, 89106
Otsuka Investigational Site
Las Vegas, Nevada, 89115
Otsuka Investigational Site
Lexington, Kentucky, 40513
Otsuka Investigational Site
Los Angeles, California, 90022
Otsuka Investigational Site
Los Angeles, California, 90025
Otsuka Investigational Site
Madison, Wisconsin, 53713
Otsuka Investigational Site
Melbourne, Florida, 32935
Otsuka Investigational Site
Meridian, Idaho, 83642
Otsuka Investigational Site
Mineola, New York, 11501
Otsuka Investigational Site
Mishawaka, Indiana, 46545
Otsuka Investigational Site
Mission, Texas, 78572
Otsuka Investigational Site
Morgantown, West Virginia, 26506
Otsuka Investigational Site
Mount Laurel, New Jersey, 08054
Otsuka Investigational Site
New Haven, Connecticut, 06510
Otsuka Investigational Site
New Orleans, Louisiana, 70121
Otsuka Investigational Site
New York, New York, 10016
Otsuka Investigational Site
New York, New York, 10021
Otsuka Investigational Site
New York, New York, 10033
Otsuka Investigational Site
Ontario, California, 91762
Otsuka Investigational Site
Paducah, Kentucky, 42003
Otsuka Investigational Site 1
Peoria, Arizona, 85381
Otsuka Investigational Site 2
Peoria, Arizona, 85381
Otsuka Investigational Site
Peoria, Illinois, 61602
Otsuka Investigational Site
Philadelphia, Pennsylvania, 19104
Otsuka Investigational Site
Plymouth, Massachusetts, 02360
Otsuka Investigational Site
Pontiac, Michigan, 48341
Otsuka Investigational Site
Port Charlotte, Florida, 33952
Otsuka Investigational Site
Port Washington, New York, 11050
Otsuka Investigational Site
Portland, Oregon, 97210
Otsuka Investigational Site
Princeton Junction, New Jersey, 08550
Otsuka Investigational Site
Providence, Rhode Island, 02904
Otsuka Investigational Site
Rapid City, South Dakota, 57701
Otsuka Investigational Site
Reno, Nevada, 89511
Otsuka Investigational Site
Rochester, Minnesota, 55905
Otsuka Investigational Site
Rochester, New York, 14642
Otsuka Investigational Site
Rockville, Maryland, 20850
Otsuka Investigational Site
Rockville, Maryland, 20852
Otsuka Investigational Site
Rosedale, New York, 11422
Otsuka Investigational Site
Royal Oak, Michigan, 48073
Otsuka Investigational Site
San Antonio, Texas, 78215
Otsuka Investigational Site
San Diego, California, 92108
Otsuka Investigational Site
Springfield, Massachusetts, 01107
Otsuka Investigational Site
St Louis, Missouri, 63110
Otsuka Investigational Site
Tampa, Florida, 33614
Otsuka Investigational Site
Tempe, Arizona, 85284
Otsuka Investigational Site
The Bronx, New York, 10467
Otsuka Investigational Site
Voorhees Township, New Jersey, 08043
Otsuka Investigational Site
Washington D.C., District of Columbia, 20037
Otsuka Investigational Site
Wheaton, Maryland, 20906
Otsuka Investigational Site
Wichita, Kansas, 67214
Otsuka Investigational Site
Winston-Salem, North Carolina, 27103
United Kingdom33 sites
Otsuka Investigational Site
Belfast, BT9 7AB
Otsuka Investigational Site
Birmingham, West Midlands, B4 6NH
Otsuka Investigational Site
Bradford, BD5 0NA
Otsuka Investigational Site
Bristol, BS2 8BJ
Otsuka Investigational Site
Cambridge, CB2 0QQ
Otsuka Investigational Site
Carshalton, Surrey, SM5 1AA
Otsuka Investigational Site
Chelmsford, CM1 7ET
Otsuka Investigational Site
Coventry, CV2 2DX
Otsuka Investigational Site
Dorchester, DT1 2JY
Otsuka Investigational Site
Edinburgh, EH16 4SA
Otsuka Investigational Site
Exeter, Devon, EX2 5DW
Otsuka Investigational Site
Hull, HU3 2JZ
Otsuka Investigational Site
Inverness, IV2 3UJ
Otsuka Investigational Site
Kirkcaldy, KY2 5AH
Otsuka Investigational Site
Leicester, LE5 4PW
Otsuka Investigational Site
Liverpool, L7 8XP
Otsuka Investigational Site
London, NW3 2QG
Otsuka Investigational Site
London, SW17 0QT
Otsuka Investigational Site
London, WC1N 3JH
Otsuka Investigational Site
Manchester, M13 9WL
Otsuka Investigational Site
Middlesbrough, TS4 3BW
Otsuka Investigational Site
Newcastle upon Tyne, NE7 7DN
Otsuka Investigational Site
Oxford, OX3 7LJ
Otsuka Investigational Site
Portsmouth, PO6 3LY
Otsuka Investigational Site
Preston, PR2 9HT
Otsuka Investigational Site
Salford, M6 8HD
Otsuka Investigational Site
Sheffield, S5 7AU
Otsuka Investigational Site
Southampton, SO16 6YD
Otsuka Investigational Site
Stevenage, SG1 4AB
Otsuka Investigational Site
Stoke-on-Trent, Staffordshire, ST4 6QG
Otsuka Investigational Site
Westcliff-on-Sea, SS0 0RY
Otsuka Investigational Site
Wolverhampton, WV10 0QP
Otsuka Investigational Site
York, North Yorkshire, YO31 8HE
Canada15 sites
Otsuka Investigational Site
Brampton, Ontario, L6Z 4N5
Otsuka Investigational Site
Edmonton, Ontario, T6G2B7
Otsuka Investigational Site
Greenfield Park, Quebec, J4V 2H1
Otsuka Investigational Site
Halifax, Nova Scotia, B3H 1V7
Otsuka Investigational Site
Montreal, Quebec, H3A 1A1
Otsuka Investigational Site
Montreal, Quebec, H3G 1A4
Otsuka Investigational Site
Montreal, Quebec, H4J 1C5
Otsuka Investigational Site
Oakville, Ontario, L6J 3M5
Otsuka Investigational Site
Scarborough Village, Ontario, M1H 3G4
Otsuka Investigational Site
St. John's, Newfoundland and Labrador, A1B 3V6
Otsuka Investigational Site
Toronto, Ontario, M4C 5T2
Otsuka Investigational Site
Toronto, Ontario, M5B 1W8
Otsuka Investigational Site
Toronto, Ontario, M5G 2N2
Otsuka Investigational Site
Vancouver, British Columbia, V5Z 1M9
Otsuka Investigational Site
Vancouver, British Columbia, V6Z 1Y2
Australia14 sites
Otsuka Investigational Site
Adelaide, South Australia, 5000
Otsuka Investigational Site
Clayton, Victoria, 3168
Otsuka Investigational Site
Launceston, Tasmania, 7250
Otsuka Investigational Site
Liverpool, New South Wales, 2170
Otsuka Investigational Site
Melbourne, Victoria, 3073
Otsuka Investigational Site
Newcastle, New South Wales, 2305
Otsuka Investigational Site
Parkville, Victoria, 3050
Otsuka Investigational Site
Perth, Western Australia, 6000
Otsuka Investigational Site
Richmond, Victoria, 3121
Otsuka Investigational Site
Sydney, New South Wales, 2031
Otsuka Investigational Site
Sydney, New South Wales, 2050
Otsuka Investigational Site
Sydney, New South Wales, 2065
Otsuka Investigational Site
Sydney, New South Wales, 2139
Otsuka Investigational Site
Westmead, New South Wales, 2145
Japan14 sites
Otsuka Investigational Site
Chiba, 260-8712
Otsuka Investigational Site
Fukuoka, 812-8582
Otsuka Investigational Site
Hokkaido, 060-8638
Otsuka Investigational Site
Kurashiki, Okayama-ken, 701-0192
Otsuka Investigational Site
Niigata, 951-8520
Otsuka Investigational Site
Osaka, 545-8586
Otsuka Investigational Site
Osaka, 565-0871
Otsuka Investigational Site
Sagamihara-shi, Kanagawa, 252-0375
Otsuka Investigational Site
Tochigi, 329-0498
Otsuka Investigational Site
Tokyo, 113-8510
Otsuka Investigational Site
Tokyo, 113-8603
Otsuka Investigational Site
Tokyo, 162-8666
Otsuka Investigational Site
Tokyo, 173-8606
Otsuka Investigational Site
Tokyo, 181-8611
Argentina13 sites
Otsuka Investigational Site
Avellaneda, Buenos Aires, 1872
Otsuka Investigational Site
Buenos Aires, C.a.b.a., C1429BWN
Otsuka Investigational Site
Buenos Aires, C1181ACH
Otsuka Investigational Site
Buenos Aires, C1425APQ
Otsuka Investigational Site
Ciudad de Buenos Aires, C1155AHD
Otsuka Investigational Site
Ciudad de Buenos Aires, C1431FWO
Otsuka Investigational Site
Córdoba, X5002HWE
Otsuka Investigational Site
Córdoba, X5016KEH
Otsuka Investigational Site
Junín, Buenos Aires, 6000
Otsuka Investigational Site
La Plata, Buenos Aires, B1902AWL
Otsuka Investigational Sites
Pergamino, Buenos Aires, 2700
Otsuka Investigational Site
Pilar, Buenos Aires, B16260DT
Otsuka Investigational Site
Sante Fe, 3000
Brazil11 sites
Otsuka Investigational Site
Belo Horizonte, Minas Gerais, 30180-060
Otsuka Investigational Site
Curitiba, Paraná, 80440-020
Otsuka Investigational Site
Joinville, Santa Catarina, 89227-680
Otsuka Investigational Site
Juiz de Fora, Minas Gerais, 36036-330
Otsuka Investigational Site
Porto Alegre, Rio Grande do Sul, 90020-090
Otsuka Investigational Site
Porto Alegre, Rio Grande do Sul, 90035-003
Otsuka Investigational Site
Porto Alegre, Rio Grande do Sul, 90610-000
Otsuka Investigational Site
São José do Rio Preto, São Paulo, 15015-200
Otsuka Investigational Site
São Paulo, São Paulo, 01246-903
Otsuka Investigational Site
São Paulo, São Paulo, 01323-001
Otsuka Investigational Site
São Paulo, 04038-002
Poland10 sites
Otsuka Investigational Site
Ciechanów, 06-400
Otsuka Investigational Site
Golub-Dobrzyń, 87-400
Otsuka Investigational Site
Krakow, 30-663
Otsuka Investigational Site
Lodz, 93-338
Otsuka Investigational Site
Radom, 26-610
Otsuka Investigational Site
Rzeszów, 35-055
Otsuka Investigational Site
Szczecin, 70-111
Otsuka Investigational Site
Warsaw, 04-730
Otsuka Investigational Site
Warsaw, 04-749
Otsuka Investigational Site
Wroclaw, 50-556
Germany8 sites
Otsuka Investigational Site
Berlin, 10117
Otsuka Investigational Site
Dresden, 01307
Otsuka Investigational Site
Düsseldorf, 40210
Otsuka Investigational Site
Erlangen, 91054
Otsuka Investigational Site
Hanover, 30625
Otsuka Investigational Site
Heidelberg, 69120
Otsuka Investigational Site
Munich, 81675
Otsuka Investigational Site
Wiesbaden, 65191
France7 sites
Otsuka Investigational Site
Caen, 14033
Otsuka Investigational Site
Grenoble, 38043
Otuska Investigational Site
Lyon, 69437
Otsuka Investigational Site
Lyon, 69473
Otsuka Investigational Site
Montpellier, 34295
Otsuka Investigational Site
Pierre-Bénite, 69495
Otsuka Investigational Site
Vandœuvre-lès-Nancy, 54511
Italy7 sites
Otsuka Investigational Site
Bologna, 40138
Otsuka Investigational Site
Lecco, 23900
Otsuka Investigational Site
Modena, 41100
Otsuka Investigational Site
Montichiari, 25018
Otsuka Investigational Site
Naples, 80131
Otsuka Investigational Site
Pavia, 27100
Otsuka Investigational Site
Rozzano, Milano, 20089
Turkey (Türkiye)6 sites
Otsuka Investigational Site
Balcali-Adana, 1330
Otsuka Investigational Site
Bornova-Izmir, 35100
Otsuka Investigational Site
Inciraltı, İzmir, 35340
Otsuka Investigational Site
Istanbul, Capa, 34390
Otsuka Investigational Site
Izmir, 35100
Otsuka Investigational Site
Sihhiye-Ankara, 6100
Czechia5 sites
Otsuka Investigational Site
České Budějovice, 370 01
Otsuka Investigational Site
Hradec Králové, 500 05
Otsuka Investigational Site
Jihlava, 586 33
Otsuka Investigational Site
Liberec, 460 63
Otsuka Investigational Site
Prague, 128 08
Spain5 sites
Otsuka Investigational Site
Alicante, 03010
Otsuka Investigational Site
Barcelona, 08036
Otsuka Investigational Site
Ciudad Real, 13005
Otsuka Investigational Site
Hospitalet de Ilobre, 08907
Otsuka Investigational Site
Madrid, 28046
Netherlands4 sites
Otsuka Investigational Site
Groningen, 9700RB
Otsuka Investigational Site
Leiden, 2333 ZA
Otsuka Investigational Site
Nijmegen, 6525 GA
Otsuka Investigational Site
Rotterdam, 3015 CE
Romania4 sites
Otsuka Investigational Site
Bucharest, 010731
Otsuka Investigational Site
Bucharest, 022328
Otsuka Investigational Site
Oradea, Bihor County, 410469
Otsuka Investigational Site
Timișoara, Timiș County, 300736
Belgium3 sites
Otsuka Investigational Site
Brussels, 1200
Otsuka Investigational Site
Ghent, 9000
Otsuka Investigational Site
Leuven, 3000
Norway2 sites
Otsuka Investigational Site
Drammen, 3004
Otsuka Investigational Site
Lillehammer, 2609
Sweden2 sites
Otsuka Investigational Site
Malmö, 20502
Otsuka Investigational Site
Stockholm, 14186
About this study
Official title: A Multi-center, Longitudinal, Observational Study of Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease Progression
To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes). Association with total kidney volume changes and other measures of disease progression will be determined in order to identify a population at increased risk for disease progression. The economic and quality life impact of ADPKD will be assessed. Subjects who terminated participation early from clinical trials with tolvaptan may also be followed.
- Medical subject headings
- Polycystic Kidney, Autosomal Dominant
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| No treatment | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation of change in total kidney volume with ADPKD-related outcomes
Measured: 1 year
Secondary outcomes (5)
Patient-reported pain
Measured: every 6 months
SF-12 Scores
Measured: every 6 months
ADPKD-Impact Scale Score
Measured: every 6 months
Cost of care
Measured: every 6 months
EQ-5D Scores
Measured: Every 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2011 (estimated)
- Study start1 Jun 2011
- Primary completion1 Oct 2014
- Study completion1 Oct 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)Studies of the same condition, open and under way.
- More trials run by Otsuka Pharmaceutical Development & Commercialization, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,409 participants (actual)
Sponsor and investigators
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Otsuka Pharmaceutical Co., Ltd.
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01430494
- Sponsor's protocol ID
- 156-10-291
- Acronym
- OVERTURE
- Status last verified
- Apr 2026
- First submitted
- 29 Jul 2011
- Last updated
- 28 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
Publications
Gitomer BY, Chonchol M, Zhou X, Garbinsky D, Wang J, Nunna S, Fernandes AW, Oberdhan D. Kidney Stone Disease and Progression Risk in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of OVERTURE. Kidney360. 2024 Sep 1;5(9):1364-1366. doi: 10.34067/KID.0000000000000524. Epub 2024 Jul 24. No abstract available.
PubMed 39752236Lioudis M, Zhou X, Davenport E, Nunna S, Krasa HB, Oberdhan D, Fernandes AW. Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis. BMC Nephrol. 2023 Jun 22;24(1):182. doi: 10.1186/s12882-023-03247-6.
PubMed 37349694Chebib FT, Zhou X, Garbinsky D, Davenport E, Nunna S, Oberdhan D, Fernandes A. Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies. Kidney Med. 2023 Apr 14;5(6):100639. doi: 10.1016/j.xkme.2023.100639. eCollection 2023 Jun.
PubMed 37250503Perrone RD, Oberdhan D, Ouyang J, Bichet DG, Budde K, Chapman AB, Gitomer BY, Horie S, Ong ACM, Torres VE, Turner AN, Krasa H. OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD. Kidney Int Rep. 2023 Feb 13;8(5):989-1001. doi: 10.1016/j.ekir.2023.02.1073. eCollection 2023 May.
PubMed 37180499
Study at a glance
From the registry record, last updated by the sponsor on 28 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-center, Longitudinal, Observational Study of Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease Progression
- ClinicalTrials.gov ID
- NCT01430494
- Acronym / sponsor ID
- OVERTURE / 156-10-291
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,409 participants (actual)
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Industry (pharma, biotech, devices)
- Collaborators
- Otsuka Pharmaceutical Co., Ltd.
- Study start
- 1 Jun 2011 (actual)
- Primary completion
- 1 Oct 2014 (actual)
- Study completion
- 1 Oct 2014 (actual)
- First posted
- 8 Sep 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes). Association with total kidney volume changes and other measures of disease progression will be determined in order to identify a population at increased risk for disease progression. The economic and quality life impact of ADPKD will be assessed. Subjects who terminated participation early from clinical trials with tolvaptan may also be followed.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| No treatment | – | – |
Who may qualify
- Ages
- 12 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Subjects will be identified by participating clinics (primarily nephrology clinics) treating patients with ADPKD.
Key inclusion criteria (2 listed)
- existing diagnosis of ADPKD by modified-Ravine criteria
- Total kidney volume >= 300 cc/m height by ultrasound or >= 250 cc/m height by MRI
Key exclusion criteria (1 listed)
- Current or expected (within the next six months) interventions for the treatment of ADPKD affecting kidney volume
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Correlation of change in total kidney volume with ADPKD-related outcomes
Time frame: 1 year
5 secondary outcomes
Patient-reported pain
Time frame: every 6 months
SF-12 Scores
Time frame: every 6 months
ADPKD-Impact Scale Score
Time frame: every 6 months
Cost of care
Time frame: every 6 months
EQ-5D Scores
Time frame: Every 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Apr 2026.
- Derived from this study: PubMed 39752236Gitomer BY, Chonchol M, Zhou X, Garbinsky D, Wang J, Nunna S, Fernandes AW, Oberdhan D. Kidney Stone Disease and Progression Risk in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of OVERTURE. Kidney360. 2024 Sep 1;5(9):1364-1366. doi: 10.34067/KID.0000000000000524. Epub 2024 Jul 24. No abstract available.
- Derived from this study: PubMed 37349694Lioudis M, Zhou X, Davenport E, Nunna S, Krasa HB, Oberdhan D, Fernandes AW. Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis. BMC Nephrol. 2023 Jun 22;24(1):182. doi: 10.1186/s12882-023-03247-6.
- Derived from this study: PubMed 37250503Chebib FT, Zhou X, Garbinsky D, Davenport E, Nunna S, Oberdhan D, Fernandes A. Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies. Kidney Med. 2023 Apr 14;5(6):100639. doi: 10.1016/j.xkme.2023.100639. eCollection 2023 Jun.
- Derived from this study: PubMed 37180499Perrone RD, Oberdhan D, Ouyang J, Bichet DG, Budde K, Chapman AB, Gitomer BY, Horie S, Ong ACM, Torres VE, Turner AN, Krasa H. OVERTURE: A Worldwide, Prospective, Observational Study of Disease Characteristics in Patients With ADPKD. Kidney Int Rep. 2023 Feb 13;8(5):989-1001. doi: 10.1016/j.ekir.2023.02.1073. eCollection 2023 May.
- Otsuka Clinical Trial WebsiteLink provided by the sponsor.
- Otsuka Clinical Trial TransparencyLink provided by the sponsor.
Related trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RecruitingObservational study
Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease (ADPKD
Active, not recruitingObservational study
Role of ROS and cAMP-PKA Biomarkers in ADPKD
Autosomal Dominant Polycystic Kidney Disease
Not yet recruitingPhase 1
A Study to Investigate the Pharmacokinetics of JMKX003142 in Healthy Participants and Participants With Hepatic Impairment
ADPKD (Autosomal Dominant Polycystic Kidney Disease), Renal Edema
RecruitingPhase 1
Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Active, not recruitingObservational study
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
266 sites in 20 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), run by Otsuka Pharmaceutical Development & Commercialization, Inc. at 266 sites in 20 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 266 sites in United States, United Kingdom, Canada, Australia, Japan and 15 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation of change in total kidney volume with ADPKD-related outcomes (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01430494, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2026.